Time: 13:11

Latest News

Nasal delivery of cannabinoids to be developed in second PreveCeutical and UniQuest agreement

Developing a soluble gel to deliver cannabinoids directly to the brain via the nasal cavity is the focus of a second research and option agreement between a Canadian company and The University of Queensland’s (UQ) main commercialisation company UniQuest. UniQuest CEO Dr Dean Moss said PreveCeutical Medical was interested in accessing UQ’s intellectual property and expertise … Continue reading Nasal delivery of cannabinoids to be developed in second PreveCeutical and UniQuest agreement

Budget key for MRFF

One of many questions to be answered in the upcoming Budget could be the future direction of the Medical Research Future Fund. The Fund, announced in the 2014-15 Budget as a $20 billion endowment to support Australian medical research, was funded from a range of health savings measures. The measures included $1.3 billion from the PBS for higher … Continue reading Budget key for MRFF

Sector concern over scrapping of 457 visas

Questions across the life sciences sector after the Turnbull government announced major changes to section 457 visas for temporary skilled migrants. In immediate changes, a number of occupations important to the life sciences sector have been removed from the list that qualify for the 457 visa. The occupations include: Biochemist; Biotechnologist, Life Scientist (General), Life Scientist (Not elsewhere classified); Nurse … Continue reading Sector concern over scrapping of 457 visas

IP Australia delays legislation

Government will not proceed with legislation designed to align and streamline the processes for obtaining, maintaining and challenging intellectual property rights, pending its response to last year’s Productivity Commission report on Australia’s IP arrangements. IP Australia has consulted widely on the Exposure Draft Intellectual Property Laws Amendment Bill 2017 and Intellectual Property Laws Amendment Regulations 2017. The Bill … Continue reading IP Australia delays legislation

Australia failing to implement trade obligations

A senior executive at US-based PhRMA has ‘called’ Australia over a failure to implement its obligations under the countries’ bilateral trade agreement. Writing on the organisation’s website, Jay Taylor, PhRMA vice president of international advocacy, explicitly pointed to Australia as one of several countries failing to live up to its trade obligations. “Ignoring these obligations erodes R&D incentives, … Continue reading Australia failing to implement trade obligations

Monash University rejects Mimotopes’ ‘administrative oversight’ claim

Monash University says Mimotopes is not being evicted from its facility due to an “administrative oversight”. The company, which is a leading provider of peptides for cancer research, says the oversight led Monash University to issue a 36-day eviction notice, giving it until 30 April to vacate the purpose-based facility. The company says eviction, which it claimed was based … Continue reading Monash University rejects Mimotopes’ ‘administrative oversight’ claim

Applications open for Bridge Program

Expressions of interest are now open for the Bridge Program. The Program, a consortium of 14 partners including global life sciences companies, venture capitalists, universities and industry associations, will be launched by QUT in June. Biotech entrepreneurs, industry professionals, research scientists and business development academics are encouraged to submit expressions of interest. Applications are due by April 28. … Continue reading Applications open for Bridge Program

New leadership for ProTA Therapeutics

Allergy immunotherapy company ProTA Therapeutics (ProTA) has announced the appointment of its new CEO. Former Mesoblast Vice President Operations, Dr Suzanne Lipe, will become ProTA’s founding CEO. Dr Lipe will drive the development and commercialisation of the company’s investigative treatment for life-threatening peanut allergy. ProTA has licensed the promising treatment developed at Melbourne’s Murdoch Children’s Research Institute by Professor … Continue reading New leadership for ProTA Therapeutics

New digital collaboration to back connected medical technologies

Companies working to improve health outcomes for patients via digital and connected medical technologies have a new support organisation following the launch of ANDHealth – a national initiative funded through the MTPConnect Project Fund Program. Established by a consortium of commercial partners, including AusBiotech and the Murdoch Children’s Research Institute, with the support MTPConnect, ANDHealth has been … Continue reading New digital collaboration to back connected medical technologies